RT Journal Article SR Electronic T1 The FREEDOM trial: In appropriate patients with diabetes and multivessel coronary artery disease, CABG beats PCI JF Cleveland Clinic Journal of Medicine JO Cleve Clin J Med FD Cleveland Clinic SP 515 OP 523 DO 10.3949/ccjm.80a.13030 VO 80 IS 8 A1 Bhuvnesh Aggarwal A1 Sachin S. Goel A1 Joseph F. Sabik A1 Mehdi H. Shishehbor YR 2013 UL http://www.ccjm.org/content/80/8/515.abstract AB The Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) trial (N Engl J Med 2012; 367:2375–2384) was designed to resolve the long-standing debate over the optimal revascularization strategy in patients with diabetes mellitus and multivessel coronary artery disease. At a median follow-up of 3.8 years, the incidence of the primary outcome (a composite of death, myocardial infarction, and stroke) was significantly lower with bypass surgery than with percutaneous intervention.